Cyndeo Wealth Partners LLC Raises Position in Eli Lilly and Company $LLY

Cyndeo Wealth Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 8.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,064 shares of the company’s stock after purchasing an additional 1,127 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $10,963,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its stake in Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. Finally, Nuveen LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $4,613,912,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 2.6%

Shares of NYSE:LLY opened at $833.08 on Friday. The stock has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The stock’s 50-day moving average price is $742.42 and its 200-day moving average price is $766.36. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. JPMorgan Chase & Co. decreased their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Morgan Stanley cut their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Guggenheim boosted their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $948.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.